The transformation of marijuana’s legal status in the U.S. is gaining momentum with its imminent reclassification to Schedule III, but what does this mean for the future of drug policy?
Story Overview
- Trump’s executive order accelerates marijuana’s shift to Schedule III.
- No confirmed reports of fentanyl being declared a weapon of mass destruction.
- The reclassification could significantly impact cannabis-related banking and taxation.
- Fentanyl remains a Schedule II drug, highlighting contrasting approaches in drug policy.
Marijuana’s Journey to Schedule III
On December 18, 2025, President Trump signed an executive order to expedite the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This move follows a series of evaluations and recommendations from the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA). The process began in October 2022 when President Biden directed a review of marijuana’s scheduling.
The timeline of events includes the HHS’s August 2023 recommendation to reclassify marijuana based on its medical benefits, such as pain relief and nausea reduction. The DEA proposed a rescheduling rule in May 2024, but progress stalled due to appeals and a postponed hearing in January 2025. Trump’s executive order aims to expedite this process, removing barriers to research and facilitating the legal use of cannabis-based products.
Implications of Reclassification
The reclassification of marijuana to Schedule III carries significant implications for the cannabis industry. Businesses currently face restrictions under the Internal Revenue Code’s Section 280E, which disallows standard business tax deductions for Schedule I and II controlled substances. Moving to Schedule III could potentially end these tax penalties, allowing cannabis companies to deduct business expenses and thus increase profitability.
Additionally, the reclassification could improve banking access for cannabis businesses. Currently, federal restrictions make it challenging for these businesses to access traditional banking services. By easing these restrictions, the industry could see expanded investment and operational growth.
Fentanyl and WMD Status: A Separate Discussion
Despite some sensational claims, no credible sources have confirmed that fentanyl has been declared a weapon of mass destruction (WMD). Fentanyl remains classified as a Schedule II controlled substance, reflecting its high potential for abuse but recognized medical use in pain management. Any potential reclassification of fentanyl as a WMD would require legislative or executive action, which has not occurred as of the latest reports.
This distinction underscores the complex landscape of U.S. drug policy. While marijuana is moving toward a less restrictive classification, fentanyl’s status remains unchanged, highlighting ongoing challenges in addressing the opioid crisis.
Industry and Policy Reactions
The cannabis industry has largely welcomed the move to expedite marijuana’s reclassification. Stakeholders view it as a significant step toward aligning federal regulations with state-level legalization and supporting industry growth. However, some experts caution that while reclassification may provide economic benefits, it does not equate to full legalization and may still leave some legal ambiguities.
Legal analysts suggest that while the end of Section 280E tax penalties would be transformative, questions remain about how swiftly these changes can be implemented. The DEA’s pending rulemaking will be crucial in determining the final impact of the executive order on the cannabis industry and its consumers.
Sources:
Buchalter: Federal Cannabis Rescheduling
Moritz Law: Federal Marijuana Rescheduling
Clark Hill: Historic Marijuana Rescheduling
